

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number:

**0 490 077 A1**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: **91118628.6**

(51) Int. Cl.<sup>5</sup> **C12N 15/11, A61K 31/70,  
C07H 21/00**

(22) Date of filing: **31.10.91**

(30) Priority: **02.11.90 US 607113  
05.04.91 US 680198  
20.05.91 US 702163**

(43) Date of publication of application:  
**17.06.92 Bulletin 92/25**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IT LI LU NL SE**

(71) Applicant: **FORYOU CORPORATION  
6-1181-2, Mukohara, Higashi  
Yamato-shi, Tokyo(JP)**

(72) Inventor: **Cho-Chung, Yoon S.  
7017 Kenhill Road  
Bethesda, Maryland 20817(US)**

(74) Representative: **Hansen, Bernd, Dr.  
Dipl.-Chem. et al  
Hoffmann, Eitle & Partner Patent- und  
Rechtsanwälte Arabellastrasse 4 Postfach  
81 04 20  
W-8000 München 81(DE)**

(54) **Antisense oligonucleotides for treatment of cancer.**

(57) RI, antisense oligonucleotides and pharmaceutical compositions thereof are disclosed. Methods for treating certain cancers in animals comprising administering to animals an effective amount of an RI, antisense oligonucleotide, or a pharmaceutical composition thereof, are also disclosed.

**EP 0 490 077 A1**

## FIELD OF THE INVENTION

The invention is in the field of medicinal chemistry. In particular, the invention relates to certain antisense oligonucleotides and the use thereof for the treatment of cancer.

## BACKGROUND OF THE INVENTION

Control mechanisms for cell growth and differentiation are disrupted in neoplastic cells (Potter, V.R. (1988) *Adv. Oncol.* 4, 1-8; Strife, A. & Clarkson, B. (1988) *Semin. Hematol.* 25, 1-19; Sachs, L. (1987) *Cancer Res.* 47, 1981-1986). cAMP, an intracellular regulatory agent, has been considered to have a role in the control of cell proliferation and differentiation (Pastan, I., Johnson, G.S. & Anderson, W.B. (1975) *Ann. Rev. Biochem.* 44, 491-522; Prasad, K.N. (1975) *Biol. Rev.* 50, 129-165; Cho-Chung, Y.S. (1980) *J. Cyclic Nucleotide Res.* 6, 163-177; Puck, T.T. (1987) *Somatic Cell Mot. Genet.* 13, 451-457). Either inhibitory or stimulatory effects of cAMP on cell growth have been reported previously in studies in which cAMP analogs such as N<sup>6</sup>-O<sup>2'</sup>-dibutyryl adenosine 3',5'-cyclic monophosphate or agents that raise intracellular cAMP to abnormal and continuously high levels were used, and available data are interpreted very differently (Chapowski, F.J., Kelly, L.A. & Butcher, R.W. (1975) *Adv. Cyclic Nucleotide Protein Phosphorylat. Res.* 6, 245-338; Cho-Chung, Y.S. (1979) in *Influence of Hormones on Tumor Development*, eds. Kellen, J.A. & Hilf, R. (CRC, Boca Raton, FL), pp. 55-93; Prasad, K.N. (1981) in *The Transformed Cell*, eds. Cameron, L.L. & Pool, T.B. (Academic, New York), pp. 235-266; Boynton, A.L. & Whitfield, J.F. (1983) *Adv. Cyclic Nucleotide Res.* 15, 193-294).

Recently, site-selective cAMP analogs were discovered which show a preference for binding to purified preparations of type II rather than type I cAMP-dependent protein kinase in vitro (Robinson-Steiner, A.M. & Corbin, J.D. (1983) *J. Biol. Chem.* 258, 1032-1040; Øgreid, D., Ekanger, R., Suva, R.H., Miller, J.P., Sturm, P., Corbin, J.D. & Døskeland, S.O. (1985) *Eur. J. Biochem.* 150, 219-227), provoke potent growth inhibition, differentiation, and reverse transformation in a broad spectrum of human and rodent cancer cell lines (Katsaros, D., Tortora, G., Tagliaferri, P., Clair, T., Ally, S., Neckers, L., Robins, R.K. & Cho-Chung, Y.S. (1987) *FEBS Lett.* 223, 97-103; Tortora, G., Tagliaferri, P., Clair, T., Colamonici, O., Neckers, L.M., Robins, R.K. & Cho-Chung, Y.S. (1988) *Blood*, 71, 230-233; Tagliaferri, P., Katsaros, D., Clair, T., Robins, R.K. & Cho-Chung, Y.S. (1988) *J. Biol. Chem.* 263, 409-416). The type I and type II protein kinases are distinguished by their regulatory subunits (RI and RII, respectively) (Corbin, J.D., Keely, S.L. & Park, C.R. (1975) *J. Biol. Chem.* 250, 218-225; Hofmann, F., Beavo, J.A. & Krebs, E.G. (1975) *J. Biol. Chem.* 250, 7795-7801). Four different regulatory subunits [RI<sub>1</sub> (previously designated RI) (Lee, D.C., Carmichael, D.F., Krebs, E.G. & McKnight, G.S. (1983) *Proc. Natl. Acad. Sci. USA* 80, 3608-3612), RI<sub>2</sub> (Clegg, C.H., Cadd, G.G. & McKnight, G.S. (1988) *Proc. Natl. Acad. Sci. USA* 85, 3703-3707), RII<sub>1</sub> (RII<sub>1</sub>) (Scott, J.D., Glaccum, M.B., Zoller, M.J., Uhler, M.D., Hofmann, D.M., McKnight, G.S. & Krebs, E.G. (1987) *Proc. Natl. Acad. Sci. USA* 84, 5192-5196) and RII<sub>2</sub> (RII<sub>2</sub>) (Jahnsen, T., Hedin, L., Kidd, V.J., Beattie, W.G., Lohmann, S.M., Walter, U., Durica, J., Schulz, T.Z., Schlitz, E., Browner, M., Lawrence, C.B., Goldman, D., Ratoosh, S.L. & Richards, J.S. (1986) *J. Biol. Chem.* 261, 12352-12361)] have now been identified at the gene-mRNA level. Two different catalytic subunits [C<sub>1</sub> (Uhler, M.D., Carmichael, D.F., Lee, D.C., Chrivia, J.C., Krebs, E.G. & McKnight, G.S. (1986) *Proc. Natl. Acad. Sci. USA* 83, 1300-1304) and C<sub>2</sub> (Uhler, M.D., Chrivia, J.C. & McKnight, G.S. (1986) *J. Biol. Chem.* 261, 15360-15363; Showers, M.O. & Maurer, R.A. (1986) *J. Biol. Chem.* 261, 16288-16291)] have also been identified; however, preferential coexpression of either one of these catalytic subunits with either the type I or type II protein kinase regulatory subunit has not been found (Showers, M.O. & Maurer, R.A. (1986) *J. Biol. Chem.* 261, 16288-16291).

The growth inhibition by site-selective cAMP analogs parallels reduction in RI<sub>1</sub> with an increase in RII<sub>2</sub>, resulting in an increase of the RII<sub>2</sub>/RI<sub>1</sub> ratio in cancer cells (Ally, S., Tortora, G., Clair, T., Grieco, D., Merlo, G., Katsaros, D., Øgreid, D., Døskeland, S.O., Jahnsen, T. & Cho-Chung, Y.S. (1988) *Proc. Natl. Acad. Sci. USA* 85, 6319-6322; Cho-Chung, Y.S. (1989) *J. Natl. Cancer Inst.* 81, 982-987).

Such selection modulation of RI<sub>1</sub> versus RII<sub>2</sub> is not mimicked by treatment with N<sup>6</sup>-O<sup>2'</sup>-dibutyryl adenosine 3',5'-cyclic monophosphate, a previously studied cAMP analog (Ally, S., Tortora, G., Clair, T., Grieco, D., Merlo, G., Katsaros, D., Øgreid, D., Døskeland, S.O., Jahnsen, T. & Cho-Chung, Y.S. (1988) *Proc. Natl. Acad. Sci. USA* 85, 6319-6322). The growth inhibition further correlates with a rapid translocation of RII<sub>2</sub> to the nucleus and an increase in the transcription of the RII<sub>2</sub> gene (Ally, S., Tortora, G., Clair, T., Grieco, D., Merlo, G., Katsaros, D., Øgreid, D., Døskeland, S.O., Jahnsen, T. & Cho-Chung, Y.S. (1988) *Proc. Natl. Acad. Sci. USA* 85, 6319-6322). These results support the hypothesis that RII<sub>2</sub> plays an important role in the cAMP growth regulatory function (Cho-Chung, Y.S. (1989) *J. Natl. Cancer Inst.* 81, 982-987).

Antisense RNA sequences have been described as naturally occurring biological inhibitors of gene expression in both prokaryotes (Mizuno, T., Chou, M.-Y., and Inouye, M. (1984), *Proc. Natl. Acad. Sci. USA* 81, (1966-1970)) and eukaryotes (Heywood, S.M. *Nucleic Acids Res.*, 14, 6771-6772 (1986)), and these sequences presumably function by hybridizing to complementary mRNA sequences, resulting in hybridization arrest of translation (Paterson, B.M., Roberts, B.E., and Kuff, E.L., (1977) *Proc. Natl. Acad. Sci. USA*, 74, 4370-4374. Antisense oligodeoxynucleotides are short synthetic nucleotide sequences formulated to be complementary to a specific gene or RNA message. Through the binding of these oligomers to a target DNA or mRNA sequence, transcription or translation of the gene can be selectively blocked and the disease process generated by that gene can be halted. The cytoplasmic location of mRNA provides a target considered to be readily accessible to antisense oligodeoxynucleotides entering the cell; hence much of the work in the field has focused on RNA as a target. Currently, the use of antisense oligodeoxynucleotides provides a useful tool for exploring regulation of gene expression in vitro and in tissue culture (Rothenberg, M., Johnson, G., Laughlin, C., Green, I., Craddock, J., Sarver, N., and Cohen, J.S.(1989) *J. Natl. Cancer Inst.*, 81:1539-1544.

## SUMMARY OF THE INVENTION

The invention is related to the discovery that inhibiting the expression of  $RI_{\alpha}$  in leukemia cells by contact with an antisense O-oligonucleotides and S-oligonucleotides for  $RI_{\alpha}$  results in the inhibition of proliferation and the stimulation of cell differentiation. Accordingly, the invention is directed to  $RI_{\alpha}$  antisense oligonucleotides and pharmaceutical compositions thereof for the treatment of cancer.

In particular, the invention is related to 15- to 30-mer antisense oligonucleotides which are complementary to a region in the first 100 N-terminal codons of  $RI_{\alpha}$  (Seq. ID No:6).

The invention is also related to 15- to 30-mer antisense oligonucleotides which are a fragment of antisense DNA complementary to  $RI_{\alpha}$  (Seq. ID No: 5).

The invention is also related to pharmaceutical compositions comprising at least one 15- to 30-mer antisense oligonucleotide which is complementary to a region in the first 100 N-terminal codons of  $RI_{\alpha}$  (Seq. ID No:6); and a pharmaceutically acceptable carrier.

The invention is also related to a method for treating cancer by suppressing growth of cancer cells susceptible to growth suppression and for inducing cancer cell differentiation in an animal comprising administering to an animal in need of such treatment a cancer cell growth suppressing amount of an  $RI_{\alpha}$  antisense oligonucleotide.

The invention also comprises the use of a 15- to 30-mer antisense oligonucleotide which is complementary to a region in the first 100 N-Terminal codons of  $RI_{\alpha}$  (Seq.ID No:6) for the preparation of a pharmaceutical suitable for treating cancer by suppressing growth of cancer cells susceptible to growth suppression in an animal including human.

## DESCRIPTION OF THE FIGURES

Fig. 1 depicts a graph showing the effect of  $RI_{\alpha}$  antisense oligodeoxynucleotide on the basal rate of growth of HL-60 leukemic cells (A) and the growth of these cells when treated with cAMP analogs or TPA (B). A, cells were grown (see the Examples) in the absence (O) or presence (\*) of  $RI_{\alpha}$  antisense oligodeoxynucleotide (15  $\mu$ M). At indicated times, cell counts in duplicate were performed. Data represent the average values  $\pm$  SD of four experiments. B, On day 4 of experiment A, cells exposed or unexposed to  $RI_{\alpha}$  antisense oligodeoxynucleotide were reseeded (day 0) at  $5 \times 10^5$  cells/dish, and cells pre-exposed to  $RI_{\alpha}$  antisense oligodeoxynucleotide were further treated with the oligomer at day 0 and day 2. cAMP analogs and TPA were added one time at day 0. Cell counts were performed on a Coulter counter on day 4. 8-Cl, 8-Cl-cAMP (10  $\mu$ M); 8-Cl +  $N^6$ -B, 8-Cl-cAMP (5  $\mu$ M) +  $N^6$ -benzyl-cAMP (5  $\mu$ M); TPA ( $10^{-8}$  M). The data represent the average values  $\pm$  SD of four experiments.

Fig. 2 depicts a graph showing the effect of  $RI_{\alpha}$  antisense oligodeoxynucleotide on the morphologic transformation of HL-60 cells. Cells either exposed or unexposed to  $RI_{\alpha}$  antisense oligodeoxynucleotide were treated with cAMP analogs or TPA as described in Fig. 1B. On day 4 (see Fig. 1B), cells were washed twice in Dulbecco's phosphate-buffered saline and were pelleted onto a glass slide by cytocentrifuge. The resulting cytopreparations were fixed and stained by Wright's stain.  $\times 180$ .

Fig. 3 depicts a Northern blot showing decreased  $RI_{\alpha}$  mRNA expression in HL-60 leukemic cells exposed to  $RI_{\alpha}$  antisense oligodeoxynucleotide. Cells were either exposed or unexposed to  $RI_{\alpha}$  antisense oligodeoxynucleotide (15  $\mu$ M) for 8 hr. Isolation of total RNA and Northern blot analysis followed the methods described in the Examples. A, ethidium bromide staining of RNA; M, markers of ribosomal

RNAs: lanes 1, 2, cells unexposed or exposed to RI<sub>α</sub> antisense oligomer. B, Northern blot analysis; the same nitrocellulose filter was hybridized to both RI<sub>α</sub> and actin probes in sequential manner. Lanes 1, 2, cells unexposed or exposed to RI<sub>α</sub> antisense oligomer.

Fig. 4 depicts an SDS-PAGE showing the effect of RI<sub>α</sub> antisense oligodeoxynucleotide on the basal and induced levels of RI<sub>α</sub> and RI<sub>β</sub> cAMP receptor proteins in HL-60 leukemic cells. Cells were either exposed to RI<sub>α</sub> antisense oligodeoxynucleotide (15 μM) or treated with cAMP analogs as described in Fig. 1. Preparation of cell extracts, the photoactivated incorporation of 8-N<sub>3</sub>-[<sup>32</sup>P]cAMP and immunoprecipitation using the anti-RI<sub>α</sub> or anti-RI<sub>β</sub> antiserum and protein A Sepharose, and SDS-PAGE of solubilized antigen-antibody complex followed the methods described in the Examples. Preimmune serum controls were carried out simultaneously and detected no immunoprecipitated band. M, <sup>14</sup>C-labeled marker proteins of known molecular weight; RI<sub>α</sub>, the 48,000 molecular weight RI (Sigma); RI<sub>β</sub>, the 56,000 molecular weight RI (Sigma). Lanes RI<sub>α</sub> and RI<sub>β</sub> are from photoaffinity labeling with 8-N<sub>3</sub>-[<sup>32</sup>P]cAMP only; lanes 1 to 3, photoaffinity labeling with 8-N<sub>3</sub>-[<sup>32</sup>P]cAMP followed by immunoprecipitation with anti-RI<sub>α</sub> or anti-RI<sub>β</sub> antiserum. 8-Cl, 8-Cl-cAMP (5 μM); N<sup>6</sup>-benzyl, N<sup>6</sup>-benzyl-cAMP (5 μM). The data in the table represent quantification by densitometric scanning of the autoradiograms. The data are expressed relative to the levels in control cells unexposed to RI<sub>α</sub> antisense oligomer and untreated with cAMP analog, which are set equal to 1 arbitrary unit. The data represent an average ± SD of three experiments. A and B, immunoprecipitation with anti-RI<sub>α</sub> and anti-RI<sub>β</sub> antisera, respectively.

Fig. 5 depicts graphs showing the growth inhibition of human cancer cell lines by RI<sub>α</sub> antisense oligodeoxynucleotide having SEQ ID No: 1 (O-oligo and S-oligo derivatives), compared to controls. Cell lines SK-N-SH, neuroblastoma; LS-174T, colon carcinoma; MCF-7, breast carcinoma; TMK-1, gastric carcinoma. E<sub>2</sub>, estradiol-17β.

Fig. 6 depicts the change in morphology of SK-N-SH human neuroblastoma cells exposed to RI<sub>α</sub> antisense oligodeoxynucleotide having SEQ ID No: 1.

Fig. 7 depicts a graph showing that RI<sub>α</sub> antisense oligodeoxynucleotide and its phosphorothioate analog inhibit the *in vivo* growth of LS-174T human colon carcinoma in athymic mice. Figure 7A shows the oligodeoxynucleotide concentration-dependent inhibition of tumor growth. O-oligo, RI<sub>α</sub> antisense oligodeoxynucleotide; S-oligo, phosphorothioate analog of RI<sub>α</sub> antisense oligomer. The cholesterol pellets (total weight 20 mg) containing the indicated doses of O-oligo or S-oligo were implanted s.c. one time, at zero time, and tumor sizes were measured. Tumor volume (see Materials and Methods, Example 3) represents an average ± S.D. of 7 tumors. Figure 7B shows the temporal effect of antisense oligodeoxynucleotide phosphorothioate analogs on tumor growth. S-oligos as indicated at 0.3 mg dose in cholesterol pellets (total weight 20 mg) were implanted s.c. 2x week, and tumor volume (see Materials and Methods, Example 3) represents an average ± S.D. of 7 tumors.

## DESCRIPTION OF THE PREFERRED EMBODIMENTS

Antisense therapy is the administration of exogenous oligonucleotides which bind to a target polynucleotide located within the cells. The term "antisense" refers to the fact that such oligonucleotides are complementary to their intracellular targets, e.g., RI<sub>α</sub>. See for example, Jack Cohen, OLIGODEOXYNUCLEOTIDES, Antisense Inhibitors of Gene Expression, CRC Press, 1989; and Synthesis 1:1-5 (1988). The RI<sub>α</sub> antisense oligonucleotides of the present invention include derivatives such as S-oligonucleotides (phosphorothioate derivatives or S-oligos, see, Jack Cohen, *supra*) which exhibit enhanced cancer cell growth inhibitory action (see Figures 5 and 7A).

S-oligos (nucleoside phosphorothioates) are isoelectronic analogs of an oligonucleotide (O-oligo) in which a nonbridging oxygen atom of the phosphate group is replaced by a sulfur atom. The S-oligos of the present invention may be prepared by treatment of the corresponding O-oligos with 3H-1,2-benzodithiol-3-one-1,1-dioxide which is a sulfur transfer reagent. See Iyer, R.P. et al., *J. Org. Chem.* 55:4693-4698 (1990); and Iyer, R.P. et al., *J. Am. Chem. Soc.* 112:1253-1254 (1990), the disclosures of which are fully incorporated by reference herein.

The RI<sub>α</sub> antisense oligonucleotides of the present invention may be RNA or DNA which is complementary to and stably hybridizes with the first 100 N-terminal codons of the RI<sub>α</sub> genome or the corresponding mRNA. Use of an oligonucleotide complementary to this region allows for the selective hybridization to RI<sub>α</sub> mRNA and not to mRNA specifying other regulatory subunits of protein kinase. Preferably, the RI<sub>α</sub> antisense oligonucleotides of the present invention are a 15 to 30-mer fragment of the antisense DNA molecule having SEQ ID NO:5 which hybridizes to RI<sub>α</sub> mRNA. Alternatively, RI<sub>α</sub> antisense oligonucleotide is a 15- to 30-mer oligonucleotide which is complementary to a region in the first 100 N-terminal codons of RI<sub>α</sub> (Seq. ID No.6). Most preferably, the RI<sub>α</sub> antisense oligonucleotide has SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, or SEQ ID

No.4.

Included as well in the present invention are pharmaceutical compositions comprising an effective amount of at least one of the RI<sub>1</sub> antisense oligonucleotides of the invention in combination with a pharmaceutically acceptable carrier. In one embodiment, a single RI<sub>1</sub> antisense oligonucleotide is utilized. In another embodiment, two RI<sub>1</sub> antisense oligonucleotides are utilized which are complementary to adjacent regions of the RI<sub>1</sub> genome. Administration of two RI<sub>1</sub> antisense oligonucleotides which are complementary to adjacent regions of the RI<sub>1</sub> genome or corresponding mRNA may allow for more efficient inhibition of RI<sub>1</sub> genomic transcription or mRNA translation, resulting in more effective inhibition of cancer cell growth.

Preferably, the RI<sub>1</sub> antisense oligonucleotide is coadministered with an agent which enhances the uptake of the antisense molecule by the cells. For example, the RI<sub>1</sub> antisense oligonucleotide may be combined with a lipophilic cationic compound which may be in the form of liposomes. The use of liposomes to introduce nucleotides into cells is taught, for example, in U.S. Patent Nos. 4,897,355 and 4,394,448, the disclosures of which are incorporated by reference in their entirety. See also U.S. Patent Nos. 4,235,871, 4,231,877, 4,224,179, 4,753,788, 4,673,567, 4,247,411, 4,814,270 for general methods of preparing liposomes comprising biological materials.

Alternatively, the RI<sub>1</sub> antisense oligonucleotide may be combined with a lipophilic carrier such as any one of a number of sterols including cholesterol, cholate and deoxycholic acid. A preferred sterol is cholesterol.

In addition, the RI<sub>1</sub> antisense oligonucleotide may be conjugated to a peptide that is ingested by cells. Examples of useful peptides include peptide hormones, antigens or antibodies, and peptide toxins. By choosing a peptide that is selectively taken up by the neoplastic cells, specific delivery of the antisense agent may be effected. The RI<sub>1</sub> antisense oligonucleotide may be covalently bound via the 5'OH group by formation of an activated aminoalkyl derivative. The peptide of choice may then be covalently attached to the activated RI<sub>1</sub> antisense oligonucleotide via an amino and sulfhydryl reactive hetero bifunctional reagent. The latter is bound to a cysteine residue present in the peptide. Upon exposure of cells to the RI<sub>1</sub> antisense oligonucleotide bound to the peptide, the peptidyl antisense agent is endocytosed and the RI<sub>1</sub> antisense oligonucleotide binds to the target RI<sub>1</sub> mRNA to inhibit translation. See PCT Application Publication No. PCT/US89/02363.

As antineoplastic agents, the RI<sub>1</sub> antisense oligonucleotides of the present invention are useful in treating a variety of cancers, including, but not limited to, gastric, pancreatic, lung, breast, anal, colorectal, head and neck neoplasms, neuroblastomas, melanoma and various leukemias.

The RI<sub>1</sub> antisense oligonucleotides of the invention may also be active against the following tumor systems: F9 teratocarcinoma, SK-N-SH neuroblastoma, TMK-1 gastric carcinoma, HL-60 promyelocytic Leukemia, Leukemia L-1210, Leukemia P388, P1534 leukemia, Friend Virus Leukemia, Leukemia L4946, Mecca lymphosarcoma, Gardner lymphosarcoma, Ridgway Osteogenic sarcoma, Sarcoma 180 (ascites), Wagner osteogenic sarcoma, Sarcoma T241, Lewis lung carcinoma, Carcinoma 755, CD8F, MCF-7 breast carcinoma, Colon 38, LS-174T colon carcinoma, Carcinoma 1025, Ehrlich carcinoma (ascites & solid), Krusby 2 carcinoma (ascites), Bashford carcinoma 63, Adenocarcinoma E 0771, B16 Melanoma, Hardin-Passey melanoma, Giloma 26, Miyona adenocarcinoma, Walker carcinosarcoma 256, Flexner-Jobling carcinoma, Jensen sarcoma, Iglesias sarcoma, Iglesias ovarian tumor, Murphy-Sturn lymphosarcoma, Yoshida sarcoma, Dunning leukemia, Rous chicken sarcoma, and Crabb hamster sarcoma.

The RI<sub>1</sub> antisense oligonucleotides and the pharmaceutical compositions of the present invention may be administered by any means that achieve their intended purpose. For example, administration may be by parenteral, subcutaneous, intravenous, intramuscular, intra-peritoneal, or transdermal routes. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.

Compositions within the scope of this invention include all compositions wherein the RI<sub>1</sub> antisense oligonucleotide is contained in an amount which is effective to achieve inhibition of proliferation and/or stimulate differentiation of the subject cancer cells. While individual needs vary, determination of optimal ranges of effective amounts of each component is with the skill of the art. Typically, the RI<sub>1</sub> antisense oligonucleotide may be administered to mammals, e.g. humans, at a dose of 0.005 to 1 mg/kg/day, or an equivalent amount of the pharmaceutically acceptable salt thereof, per day of the body weight of the mammal being treated.

In addition to administering the RI<sub>1</sub> antisense oligonucleotides as a raw chemical in solution, the RI<sub>1</sub> antisense oligonucleotides may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the RI<sub>1</sub> antisense oligonucleotide into preparations which can be used pharmaceutically.

Suitable formulations for parenteral administration include aqueous solutions of the RI<sub>1</sub> antisense

oligonucleotides in water-soluble form, for example, water-soluble salts. In addition, suspensions of the active compounds as appropriate oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, for example, sesame oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers.

The antisense oligonucleotides of the present invention may be prepared according to any of the methods that are well known to those of ordinary skill in the art. Preferably, the antisense oligonucleotides are prepared by solid phase synthesis. See, Goodchild, J., *Bioconjugate Chemistry*, 1:165-167 (1990), for a review of the chemical synthesis of oligonucleotides. Alternatively, the antisense oligonucleotides can be obtained from a number of companies which specialize in the custom synthesis of oligonucleotides.

Having now generally described this invention, the same will be understood by reference to an example which is provided herein for purposes of illustration only and is not intending to be limited unless otherwise specified. The entire text of all applications, patents and publications, if any, cited above and below are hereby incorporated by reference.

## EXAMPLES

### Example 1

**Oligodeoxynucleotides.** The 21-mer oligodeoxynucleotides used in the present studies were synthesized at Midland Certified Reagent Co. (Midland, TX) and had the following sequences: human  $RI_{\alpha}$  - (Sandberg, M., Tasken, K., Oyen, O., Hansson, V. & Jahnsen, T. (1987) *Biochem. Biophys. Res. Commun.* 149, 939-945) antisense, 5'-GGC-GGT-ACT-GCC-AGA-CTC-CAT-3' (SEQ ID No:1); human  $RII_{\beta}$  (Levy, F.O., Oyen, O., Sandberg, M., Tasken, K., Eskild, W., Hansson, V. & Jahnsen, T. (1988) *Mol. Endocrinol.*, 2, 1364-1373) antisense 5'-CGC-CGG-GAT-CTC-GAT-GCT-CAT-3'; human  $RII_{\alpha}$  (Oyen, O., Myklebust, F., Scott, J. D., Hansson, V. & Jahnsen, T. (1989) *FEBS Lett.* 246, 57-64) antisense, 5'-CGG-GAT-CTG-GAT-GTG-GCT-CAT-3'; and the random sequence oligodeoxynucleotide was made of a mixture of all four nucleotides at every position.

**Cell Growth Experiment.** Cells grown in suspension culture in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, penicillin (50 U/ml), streptomycin (500  $\mu$ g/ml), and 1 mM glutamine (Gibco, Grand Island, NY) were seeded at  $5 \times 10^5$  cells per dish. Oligodeoxynucleotides were added after seeding and every 48 hr thereafter. Cell counts were performed on a Coulter counter. Cells unexposed or exposed to oligodeoxynucleotides for 4 days were reseeded (day 0) at  $5 \times 10^5$  cells/dish, and cells pre-exposed to the oligodeoxynucleotide were further treated with the oligomer at day 0 and day 2. cAMP analogs (kindly provided by Dr. R.K. Robins, Nucleic Acid Research Institute, Costa Mesa, CA) or 12-O-tetradecanoylphorbol-13-acetate (TPA) were added one time at day 0. Cell counts were performed on day 4.

**Immunoprecipitation of  $RI_{\alpha}$  and  $RII_{\beta}$  cAMP Receptor Proteins after Photoaffinity Labeling with 8- $N_3$ -[ $^{32}$ P]cAMP.** Cell extracts were prepared at 0-4°C. The cell pellets ( $2 \times 10^6$  cells), after two washes with PBS, were suspended in 0.5 ml buffer Ten (0.1 M NaCl, 5 mM  $MgCl_2$ , 1% Nonidet P-40, 0.5% Na deoxycholate, 2 KIU/ml bovine aprotinin, and 20 mM Tris-HCl, pH 7.4) containing proteolysis inhibitors (Tortora, G., Clair, T. & Cho-Chung, Y. S. (1990) *Proc. Natl. Acad. Sci. USA* 87, 705-708), vortex-mixed, passed through a 22-gauge needle 10 times, allowed to stand for 30 min at 4°C, and centrifuged at  $750 \times g$  for 20 min; the resulting supernatants were used as cell lysates. The photoactivated incorporation of 8- $N_3$ -[ $^{32}$ P]cAMP (60.0 Ci/mmol), and the immunoprecipitation using the anti- $RI_{\alpha}$  or anti- $RII_{\beta}$  antiserum (kindly provided by Dr. S.O. Døskeland, University of Bergen, Bergen, Norway) and protein A Sepharose and SDS-PAGE of solubilized antigen-antibody complex followed the method previously described (Tortora, G., Clair, T. & Cho-Chung, Y. S. (1990) *Proc. Natl. Acad. Sci. USA* 87, 705-708; Ekanger, R., Sand, T. E., Ogreid, D., Christoffersen, T. & Døskeland, S.O. (1985) *J. Biol. Chem.* 260, 3393-3401).

**cAMP-Dependent Protein Kinase Assays.** After two washes with Dulbecco's phosphate-buffered saline, cell pellets ( $2 \times 10^6$  cells) were lysed in 0.5 ml of 20 mM Tris (pH 7.5), 0.1 mM sodium EDTA, 1 mM dithiothreitol, 0.1 mM pepstatin, 0.1 mM antipain, 0.1 mM chymostatin, 0.2 mM leupeptin, 0.4 mg/ml aprotinin, and 0.5 mg/ml soybean trypsin inhibitor, using 100 strokes of a Dounce homogenizer. After centrifugation (Eppendorf 5412) for 5 min, the supernatants were adjusted to 0.7 mg protein/ml and assayed (Uhlir, M. D. & McKnight, G. S. (1987) *J. Biol. Chem.* 262, 15202-15207) immediately. Assays (40  $\mu$ l total volume) were performed for 10 min at 30°C and contained 200  $\mu$ M ATP,  $2.7 \times 10^6$  cpm  $\gamma$ -[ $^{32}$ P]ATP, 20 mM  $MgCl_2$ , 100  $\mu$ M Kempide (Sigma K-1127) (Kemp, B. E., Graves, D. J., Benjamin, E. & Krebs, E. G. (1977)

J. Biol. Chem. 252, 4888-4894), 40 mM Tris (pH 7.5),  $\pm$  100  $\mu$ M protein kinase inhibitor (Sigma P-3294) (Cheng, H.-C., Van Patten, S. M., Smith, A. J. & Walsh, D. A. (1985) *Biochem. J.* 231, 655-661),  $\pm$  8  $\mu$ M cAMP and 7  $\mu$ g of cell extract. The phosphorylation of Kemptide was determined by spotting 20  $\mu$ l of incubation mixture on phosphocellulose filters (Whatman, P81) and washing in phosphoric acid as described (Roskoski, R. (1983) *Methods Enzymol.* 99, 3-6). Radioactivity was measured by liquid scintillation using Econofluor-2 (NEN Research Products NEF-969).

**Isolation of Total RNA and Northern Blot Analysis.** The cells ( $10^8$  washed twice with phosphate-buffered saline) were lysed in 4.2 M guanidine isothiocyanate containing 25 mM sodium citrate (pH 7.0), 0.5% sarcosyl (*N*-lauroylsarcosine Na<sup>+</sup>), and 0.1 M  $\beta$ -mercaptoethanol, and the lysates were homogenized, and total cellular RNA was sedimented through a CsCl cushion (5.7 M CsCl, 10 mM EDTA) as described by Chirgwin *et al.* (Chirgwin, J. M., Przybyla, A. E., MacDonald, R. Y. & Rutter, W. J. (1977) *Biochemistry* 18, 5284-5288). Total cellular RNA containing 20 mM 3-[*N*-morpholine]propane-sulfonic acid (pH 7.0), 50% formamide, and 6% formaldehyde was denatured at 65°C for 10 min and electrophoresed through a denaturing 1.2% agarose-2.2 M formaldehyde gel. The gels were then transferred to Biotrans nylon membranes (ICN Biomedicals) by the method of Thomas (Thomas, P. S. (1980) *Proc. Natl. Acad. Sci. USA* 77, 5201-5205) and hybridized to the following two <sup>32</sup>P-labeled nick-translated cDNA probes: 1.5 kilobase (kb) cDNA clone containing the entire coding region for the human cAMP-dependent protein kinase type I regulatory subunit, RI<sub>α</sub> (Sandberg, M., Tasken, K., Oyen, O., Hansson, V. & Jahnsen, T. (1987) *Biochem. Biophys. Res. Commun.* 149, 939-945) (kindly provided by Dr. T. Jahnsen, Institute of Pathology, Rikshospitalet, Oslo, Norway), and human  $\beta$  actin (Oncor p7000  $\beta$  actin).

## RESULTS

The RI<sub>α</sub> antisense oligodeoxynucleotide at 15  $\mu$ M concentration had immediate effects on the rate of proliferation of HL-60 cells. By 4-5 days in culture, while cells unexposed to RI<sub>α</sub> antisense oligomer demonstrated an exponential rate of growth, cells exposed to the antisense oligomer exhibited a reduced growth rate and eventually stopped replicating (Fig. 1A). This inhibitory effect on cell proliferation persisted throughout the culture period. The growth inhibition was not due to cell killing; cells were over 90% viable after exposure to RI<sub>α</sub> antisense oligomer (15  $\mu$ M) for 7 days as assessed by flow cytometry using forward and side scatter. RI<sub>α</sub> sense, RI<sub>α</sub>, or RI<sub>α</sub> antisense, or a random sequence oligodeoxynucleotide had no such growth inhibitory effect.

Cells unexposed or exposed to RI<sub>α</sub> antisense oligodeoxynucleotide for 4 days in culture were reseeded and examined for their response to treatment with cAMP analogs or TPA. In cells unexposed to RI<sub>α</sub> antisense oligodeoxynucleotide, 8-Cl-cAMP (10  $\mu$ M) produced 60% growth inhibition, and 80% growth inhibition was achieved by 8-Cl-cAMP (5  $\mu$ M) plus *N*<sup>6</sup>-benzyl-cAMP (5  $\mu$ M) (Fig. 1B) (Tortora, G., Tagliaferri, P., Clair, T., Colamonici, O., Neckers, L. M., Robins, R. K. & Cho-Chung, Y. S. (1988) *Blood* 71, 230-233), and TPA ( $10^{-8}$  M) exhibited 60% growth inhibition (Fig. 1B). In contrast, cells exposed to antisense oligodeoxynucleotide exhibited retarded growth (25% the rate of growth of cells unexposed to the antisense oligomer) and neither cAMP analogs nor TPA brought about further retardation of growth (Fig. 1B).

HL-60 cells undergo a monocytic differentiation upon treatment with site-selective cAMP analogs. Cells either unexposed or exposed to RI<sub>α</sub> antisense oligodeoxynucleotide were examined for their morphology before and after treatment with cAMP analogs. As shown in Fig. 2, in cells unexposed to RI<sub>α</sub> antisense oligomer, 8-Cl-cAMP plus *N*<sup>6</sup>-benzyl-cAMP induced a monocytic morphologic change characterized by a decrease in nuclear-to-cytoplasm ratio, abundant ruffled and vacuolated cytoplasm, and loss of nucleoli. Strikingly, the same morphologic change was induced when cells were exposed to RI<sub>α</sub> antisense oligodeoxynucleotide (Fig. 2). Moreover, the morphologic changes induced by antisense oligomer were indistinguishable from that induced by TPA (Fig. 2).

To provide more evidence that the growth inhibition and monocytic differentiation induced in HL-60 cells exposed to the RI<sub>α</sub> antisense oligodeoxynucleotide were due to an intracellular effect of the oligomer, the RI<sub>α</sub> mRNA level was determined. As shown in Fig. 3, 3.0 kb RI<sub>α</sub> mRNA (Sandberg, M., Tasken, K., Oyen, O., Hansson, V. & Jahnsen, T. (1987) *Biochem. Biophys. Res. Commun.* 149, 939-945) was virtually undetectable in cells exposed for 8 hr to RI<sub>α</sub> antisense oligodeoxynucleotide (Fig. 3B, lane 2), and the decrease in RI<sub>α</sub> mRNA was not due to a lower amount of total RNA as shown by the ethidium bromide staining (compare lane 2 with lane 1 of Fig. 3A). Conversely, an enhanced level of actin mRNA was detected in cells exposed to RI<sub>α</sub> antisense oligomer (Fig. 3B). Whether the increase in actin mRNA level represents changes in cytoskeletal structure is not known.

The levels of cAMP receptor proteins in these cells was then determined by immunoprecipitation using

anti-RI<sub>β</sub> and anti-RII<sub>β</sub> antisera (Tortora, G., Clair, T. & Cho-Chung, Y. S. (1990) *Proc. Natl. Acad. Sci. USA* 87, 705-708; Ekanger, R., Sand, T. E., OGREID, D., Christoffersen, T. & Døskeland, S.O. (1985) *J. Biol. Chem.* 260, 3393-3401) after photoaffinity labeling of these receptor proteins with 8-N<sub>3</sub>-[<sup>32</sup>P]cAMP. In control cells, treatment with 8-C1-cAMP plus N<sup>6</sup>-benzyl-cAMP brought about a 70% reduction in RI<sub>β</sub> with a 3-fold increase in RII<sub>β</sub>, resulting in a 10-fold increase in the ratio of RII<sub>β</sub>/RI<sub>β</sub> (Fig. 4) (Cho-Chung, Y. S. (1989) *J. Natl. Cancer Inst.* 81, 982-987). Exposure of these cells to RI<sub>β</sub> antisense oligodeoxynucleotide for 4 days brought about marked changes in both RI<sub>β</sub> and RII<sub>β</sub> levels; an 80% reduction in RI<sub>β</sub> with a 5-fold increase in RII<sub>β</sub> resulted in a 25-fold increase in the ratio of RII<sub>β</sub>/RI<sub>β</sub> compared with that in control cells (Fig. 4). Since growth inhibition and differentiation were appreciable after 3-4 days of exposure to RI<sub>β</sub> antisense oligomer, the changing levels of RI<sub>β</sub> and RII<sub>β</sub> proteins appears to be an early event necessary for commitment to differentiation.

Data in Fig. 4 showed that suppression of RI<sub>β</sub> by the antisense oligodeoxynucleotide brought about a compensatory increase in RII<sub>β</sub> level. Such coordinated expression of RI and RII without changes in the amount of C subunit has been shown previously (Hofman, F., Bechtel, P. J. & Krebs, E. G. (1977) *J. Biol. Chem.* 252, 1441-1447; Otten, A. D. & Mcknight, G. S. (1989) *J. Biol. Chem.* 264, 20255-20260). The increase in RII<sub>β</sub> may be responsible for the differentiation induced in these cells after exposure to RI<sub>β</sub> antisense oligodeoxynucleotide. The increase in RII<sub>β</sub> mRNA or RII<sub>β</sub> protein level has been correlated with cAMP analog-induced differentiation in K-562 chronic myelocytic leukemic cells (Tortora, G., Clair, T., Katsaros, D., Ally, S., Colamonici, O., Neckers, L. M., Tagliaferri, P., Jahnsen, T., Robins, R. K. & Cho-Chung, Y. S. (1989) *Proc. Natl. Acad. Sci. USA* 86, 2849-2852) and in erythroid differentiation of Friend erythrocytic leukemic cells (Schwartz, D. A. & Rubin, C. S. (1985) *J. Biol. Chem.* 260, 6296-6303). In a recent report (Tortora, G., Clair, T. & Cho-Chung, Y. S. (1990) *Proc. Natl. Acad. Sci. USA* 87, 705-708), we have provided direct evidence that RII<sub>β</sub> is essential for the cAMP-induced differentiation in HL-60 cells. HL-60 cells that were exposed to RII<sub>β</sub> antisense oligodeoxynucleotide became refractory to treatment with cAMP analogs and continued to grow.

The essential role of RII<sub>β</sub> in differentiation of HL-60 cells was further demonstrated when these cells were exposed to both RI<sub>β</sub> and RII<sub>β</sub> antisense oligodeoxynucleotides simultaneously. As shown in Table 1, RI<sub>β</sub> antisense oligodeoxynucleotide induced a marked increase in the expression of monocytic surface antigens [Leu 15 (Landay, A., Gartland, L. & Clement, L. T. (1983) *J. Immunol.* 131, 2757-2761) and Leu M3 (Dimitriu-Bona, A., Burmester, G. R., Waters, S. J. & Winchester, R. J. (1983) *J. Immunol.* 130, 145-152)] along with a decrease in markers related to the immature myelogenous cells [My9 (Talle, M. A., Rao, P. E., Westberg, E., Allegar, N., Makowski, M., Mittler, R. S. & Goldstein, G. (1983) *Cell. Immunol.* 78, 83.; Todd, R. F. III, Griffin, J. D., Ritz, J., Nadler, L. M., Abrams, T. & Schlossman, S. F. (1981) *Leuk. Res.* 5, 491)]. These changes in surface marker expression were abolished when cells were exposed simultaneously to both RI<sub>β</sub> and RII<sub>β</sub> antisense oligodeoxynucleotides (Table 1). RII<sub>β</sub> cAMP receptor was not detected in HL-60 cells (Cho-Chung, Y. S., Clair, T., Tagliaferri, P., Ally, S., Katsaros, D., Tortora, G., Neckers, L., Avery, T. L., Crabtree, G. W. & Robins, R. K. (1989) *Cancer Invest.* 7(2), 161-177), and RII<sub>β</sub> antisense oligodeoxynucleotide showed no interference with the effects of RI<sub>β</sub> antisense oligomer (Table 1).

Cells exposed to both RI<sub>β</sub> and RII<sub>β</sub> antisense oligodeoxynucleotides were neither growth inhibited nor differentiated regardless of cAMP analog treatment. We interpret these results to reflect the blockage of cAMP-dependent growth regulatory pathway. Cells under these conditions are no longer cAMP-dependent but survive and proliferate probably through an alternate pathway. Thus, suppression of both RI<sub>β</sub> and RII<sub>β</sub> gene expression led to an abnormal cellular growth regulation similar to that in mutant cell lines (Gottesman, M. M. (1980) *Cell* 22, 329-330), those that contain either deficient or defective regulatory subunits of cAMP-dependent protein kinase and are no longer sensitive to cAMP stimulus.

Our results demonstrated that cAMP transduces signals for dual controls, either positive or negative, on cell proliferation, depending on the availability of RI<sub>β</sub> or RII<sub>β</sub> receptor proteins. The RI<sub>β</sub> antisense oligodeoxynucleotide which brought about suppression of RI<sub>β</sub> along with enhancement of RII<sub>β</sub> expression led to terminal differentiation of HL-60 leukemia with no sign of cytotoxicity.

It is unlikely that free C subunit increase in cells exposed to RI<sub>β</sub> antisense oligodeoxynucleotide was responsible for the differentiation, because cells exposed to RII<sub>β</sub> antisense or both RI<sub>β</sub> and RII<sub>β</sub> antisense oligodeoxynucleotides, conditions which also would produce free C subunit, continued to grow and became refractory to cAMP stimulus. In order to directly verify this we measured phosphotransferase activity in cells that are exposed or unexposed to the antisense oligodeoxynucleotides using kemptide (Kemp, B. E., Graves, D. J., Benjamin, E. & Krebs, E. G. (1977) *J. Biol. Chem.* 252, 4888-4894) as a substrate in the presence and absence of a saturating concentration of cAMP and in the presence and absence of the heat-stable protein kinase inhibitor (Cheng, H.-C., Van Patten, S. M., Smith, A. J. & Walsh, D. A. (1985) *Biochem. J.* 231, 655-661). This method of assay gives accurate determination of the relative levels of dissociated C



and total C activity. Cell extracts from untreated HL-60 cells exhibited a very low level of dissociated C and were stimulated 36-fold by cAMP (Table 2). This cAMP-stimulated activity was almost completely inhibited by the heat-stable protein kinase inhibitor (Table 2), indicating that the total C activity measured was cAMP-dependent protein kinase. In cells exposed to RI<sub>α</sub> antisense, RII<sub>β</sub> antisense, or RI<sub>α</sub> and RII<sub>β</sub> antisense oligodeoxynucleotide, the free C activity was not increased as compared to unexposed control cells, although there was a small difference in the total cAMP-stimulated activity (Table 2). These results provide direct evidence that free catalytic subunit is not responsible for the differentiation observed in HL-60 cells.

Over expression of RI<sub>α</sub> cAMP receptor protein has also been found in the majority of human breast and colon primary carcinomas examined (Bradbury, A. W., Miller, W. R., Clair, T., Yokozaki, H. & Cho-Chung, Y. S. (1990) *Proc. Am. Assoc. Cancer Res.* 31, 172), suggesting an important *in vivo* role of cAMP receptor in tumor growth as well. However, the precise role of RI<sub>α</sub> in cell proliferation is not known at present. RI<sub>α</sub> may suppress RII<sub>β</sub> production by titrating out C subunit, or it may be a transducer of mitogenic signals leading to cell proliferation. Our results demonstrate that RI<sub>α</sub> antisense oligodeoxynucleotide provides a useful genetic tool for studies on the role of cAMP receptor proteins in cell proliferation and differentiation, and contribute to a new approach in the control of malignancy.

Table 1.

| Modulation of differentiation markers in HL-60 cells by RI <sub>α</sub> antisense oligodeoxynucleotide |                |       |     |
|--|----------------|-------|-----|
| Treatment  | Surface Makers |       |     |
|  | Leu15          | LeuM3 | My9 |
| Control  | 10             | 2     | 100 |
| RI <sub>α</sub> antisense  | 80             | 98    | 80  |
| RI <sub>α</sub> antisense + RII <sub>β</sub> antisense   | 11             | 2     | 100 |
| RII <sub>β</sub> antisense   | 13             | 3     | 100 |
| RI <sub>α</sub> antisense + RII <sub>β</sub> antisense   | 85             | 100   | 80  |

Surface antigen analysis was performed by flow cytometry using monoclonal antibodies reactive with either monocytic or myeloid cells. The monoclonal antibodies used were Leu 15, Leu M3, and My9.  $2 \times 10^4$  cells were analyzed for each sample, and cell gating was performed using forward and side scatter. The numbers represent % positive and represent the average values of three experiments.

Table 2. Protein kinase activity in HL-60 cells

| Treatment                                      | Activity<br>-cAMP | Relative<br>to control | Activity<br>+cAMP | Relative<br>to control | Stimulation<br>(fold) |
|--|-------------------|------------------------|-------------------|------------------------|-----------------------|
| - PKI  |                   |                        |                   |                        |                       |
| Control  | 23.0 $\pm$ 6.6    | 1.0                    | 837 $\pm$ 87      | 1.0                    | 36                    |
| RI $_{\alpha}$ antisense                       | 22.9 $\pm$ 5.4    | 1.0                    | 944 $\pm$ 18      | 1.1                    | 41                    |
| RII $_{\beta}$ antisense                       | 22.8 $\pm$ 8.4    | 1.0                    | 1,028 $\pm$ 154   | 1.2                    | 45                    |
| RI $_{\alpha}$ and<br>RII $_{\beta}$ antisense | 24.3 $\pm$ 7.0    | 1.1                    | 802 $\pm$ 36      | 1.0                    | 33                    |
| + PKI  |                   |                        |                   |                        |                       |
| Control  | 17.5 $\pm$ 8.7    | 1.0                    | 37.0 $\pm$ 8.4    | 1.0                    | 2.1                   |
| RI $_{\alpha}$ antisense                       | 25.0 $\pm$ 8.8    | 1.4                    | 22.6 $\pm$ 8.8    | 0.6                    | 0.9                   |
| RII $_{\beta}$ antisense                       | 24.0 $\pm$ 2.6    | 1.4                    | 24.8 $\pm$ 3.9    | 0.7                    | 1.0                   |
| RI $_{\alpha}$ and<br>RII $_{\beta}$ antisense | 19.0 $\pm$ 5.9    | 1.1                    | 19.1 $\pm$ 8.2    | 0.5                    | 1.0                   |

Cells were exposed to each of 15  $\mu$ M concentrations of RI $_{\alpha}$ , RII $_{\beta}$ , or RI $_{\alpha}$  and RII $_{\beta}$  antisense oligodeoxynucleotide for 4 days as shown in Fig. 1A. The data represent an average  $\pm$  SD of duplicate determinations of three identical experiments.

\*Picomoles phosphate transferred to Kemptide per min/mg protein.

#### Example 2

Next, the RI $_{\alpha}$  antisense oligonucleotide having SEQ ID NO:1 was administered to mice having an experimental tumor. A pellet of RI $_{\alpha}$  antisense oligonucleotide (25 mg/kg) and cholesterol (1000 mg/kg) was implanted s.c. in the left flank of athymic mice which had been injected in the right flank with LS-174T human colon cancer cells ( $2 \times 10^6$  cells) suspended in phosphate-buffered saline. Tumor measurements and mouse weights were recorded on the initial day of treatment (staging day), and at the end of treatment (staging day +5). The mean tumor weight change ( $\Delta$ ), was based on length and width measurements in millimeters. After a few days, the tumor growth was inhibited when compared to control cells (see Table 3). No change in body weight was noted in the control and treated animals.

Table 3.

| Effect of RI <sub>2</sub> antisense oligodeoxynucleotide s.c. pellet on the growth of LS-174T human colon carcinoma in athymic mice |  |  |                    |
|---|--|--|--------------------|
|   | Initial mean <sup>c</sup><br>tumor wt (mg) | Final mean <sup>d</sup> %<br>tumor wt (mg) | ΔT/ΔC <sup>e</sup> |
| Treatment <sup>a</sup> s.c. pellet implanted  |  |  |                    |
| Control   | 25   | 450  | --                 |
| RI <sub>2</sub> antisense (0.5 mg)  | 25   | 230  | 48                 |
| 8-Cl cAMP (1 mg) <sup>b</sup> + N <sup>6</sup> benzyl cAMP (1 mg)   | 34   | 250  | 51                 |

a. 20 mg pellet lyophilized consisting of indicated doses of RI<sub>2</sub> antisense or cAMP analogs plus supplement doses of cholesterol.

b. The growth inhibitory effect of these cAMP analogs correlate with decrease in RI<sub>2</sub> (Natl. Cancer Inst. 81 982 (1989)) and is shown here for comparison.

c. Mean tumor weight per group (4 mice) on staging day.

d. Mean tumor weight per group on staging day + 5.

e. % of change in test tumor weight (ΔT)/change in control tumor weight (ΔC).

In other *in vitro* experiments, the RI<sub>2</sub> antisense oligonucleotide having SEQ ID NO: 1 was added to dishes containing neuroblastoma, colon carcinoma, breast carcinoma and gastric carcinoma cells. As shown in Figure 5, the RI<sub>2</sub> antisense oligonucleotide having SEQ ID No: 1 inhibited proliferation of all cancer cell types when compared to control cells. Moreover, the RI<sub>2</sub> antisense oligonucleotide having SEQ ID No: 1 caused differentiation of the human neuroblastoma cells (see Figure 6).

### Example 3

Next, the effect of O-oligo and S-oligo RI<sub>2</sub> antisense oligonucleotides on the growth of LS-174T human colon carcinoma in athymic mice was compared.

**Materials and Methods.** We synthesized [Milligen Biosearch 8700 DNA synthesizer (Bedford, MA)] the 21-mer antisense oligodeoxynucleotides and their phosphorothioate analogs complementary to the human RI<sub>2</sub> human RII<sub>2</sub> mRNA transcripts starting from the first codon, and mismatched sequence (random) oligomers of identical size. The oligomers had the following sequences: RI<sub>2</sub> antisense, 5'-GGC-GGT-ACT-GCC-AGA-CTC-CAT-3'; RII<sub>2</sub> antisense, 5'-CGC-CGG-GAT-CTC-GAT-GCT-CAT-3'; and random oligo, 5'-CGA-TCG-ATC-GAT-CGA-TCG-TAC-3'.

LS-174T human colon carcinoma cells ( $2 \times 10^6$ ) were injected s.c. in athymic mice, and the antisense oligodeoxynucleotides in the form of either a cholesterol pellet or 50% sesame oil emulsion were administered s.c. 1 week later when mean tumor sizes usually were 25-50 mg. Tumor volume was based on length and width measurements and calculated by the formula  $4/3 \pi r^3$ , where  $r = (\text{length} + \text{width})/4$ .

**Results and Discussion.** Fig. 7 shows the dose- and time-dependent effect of an RI<sub>2</sub> antisense oligodeoxynucleotide (O-oligo) at 0.2 and 0.5 mg doses in cholesterol pellets administered s.c. one time (at zero time); it brought about 20 and 46% growth inhibition, respectively, in 7 days when compared with control (untreated) tumors (Fig. 7A). Strikingly, the RI<sub>2</sub> antisense phosphorothioate analog (S-oligo) at a 0.2 mg dose (cholesterol pellet, s.c.) gave a 60% growth inhibition at day 7, exhibiting a 3-fold greater potency than the O-oligo antisense (Fig. 7A). The growth inhibitory effect of RI<sub>2</sub> antisense S-oligo was even greater when animals were treated for a longer period. The RI<sub>2</sub> antisense S-oligo at a 0.3 mg dose in a cholesterol pellet, 2 times week s.c. implantation for 3 weeks, resulted in a 80% growth inhibition; the tumor growth almost stopped after 2 weeks of treatment (Fig. 7B). RI<sub>2</sub> antisense O-oligo or S-oligo administered s.c. as 50% sesame oil emulsion gave similar results. RI<sub>2</sub> antisense S-oligo brought about no apparent toxicity in animals; no body weight loss or other toxic symptoms were observed during the 3 weeks of treatment.

The growth inhibitory effect brought about by RI<sub>2</sub> antisense S-oligo was the specific effect of the oligomer. RII<sub>2</sub> antisense or random (mismatched sequence) S-oligos of the identical size as the RI<sub>2</sub> antisense oligomer had no effect on the tumor growth (Fig. 7B).

To provide more evidence that the growth inhibition observed in colon carcinomas in athymic mice treated with RI<sub>2</sub> antisense oligodeoxynucleotide was due to an intracellular effect of the oligomer, the levels

of RI<sub>α</sub> and RII<sub>β</sub> cAMP receptor proteins in these tumors were determined. RI<sub>α</sub> levels were determined by immunoblotting (Ally, S., Proc. Natl. Acad. Sci. USA 85:6319-6322 (1988)) using monoclonal antibody against human RI<sub>α</sub> (kindly provided by Drs. T. Lea, University of Oslo, Oslo, Norway, and S.O. Døskeland, University of Bergen, Bergen, Norway), and RII<sub>β</sub> was measured by immunoprecipitation (Tortora, G., et al., Proc. Natl. Acad. Sci. USA 87:705-708 (1990)) with anti-RII<sub>β</sub> antiserum (kindly provided by Dr. S.O. Døskeland) after photoaffinity labeling of RII<sub>β</sub> with [<sup>32</sup>P], 8-N<sub>3</sub>-cAMP. As shown in Table 4, RI<sub>α</sub> antisense S-oligomer treatment brought about a marked reduction (80% decrease) of RI<sub>α</sub> level in tumors as compared with that in untreated control tumors. This suppression of RI<sub>α</sub> expression by RI<sub>α</sub> antisense S-oligomer brought about a 2-fold increase in RII<sub>β</sub> level (Table 4). Such coordinated expression of RI<sub>α</sub> and RII<sub>β</sub> without changes in the amount of catalytic subunit of protein kinase has been shown in HL-60 leukemia cells that demonstrated growth inhibition and differentiation upon exposure to RI<sub>α</sub> antisense oligodeoxynucleotide. On the other hand, a 50% increase in RI<sub>α</sub> level along with 80% suppression in RII<sub>β</sub> level was observed in tumors after treatment with RII<sub>β</sub> antisense S-oligomer (Table 4) which had no effect on tumor growth (Fig. 7). Random (mismatched sequence) S-oligomer which had no effect on tumor growth (Fig. 7) also showed no effect on RI<sub>α</sub> levels (Table 4). Thus, reduction in RI<sub>α</sub> expression appears to trigger a decrease or halt in tumor growth upon treatment with RI<sub>α</sub> antisense oligomer. Our results demonstrated that cAMP transduces signals for dual control, either positive or negative, on cell proliferation, depending on the availability of RI<sub>α</sub> or RII<sub>β</sub> receptor proteins. The RI<sub>α</sub> antisense oligodeoxynucleotide, which suppressed RI<sub>α</sub> and enhanced RII<sub>β</sub> expression, led to inhibition of *in vivo* growth of solid colon carcinoma in athymic mice with no symptoms of toxicity in animals. The phosphorothioate analog (S-oligo) of RI<sub>α</sub> antisense oligomer exhibited a greater potency than the antisense of unmodified oligodeoxynucleotide (O-oligo). It has been shown that S-oligos, as compared with O-oligos, more readily enter cells, are more resistant to endonucleases, and yet exhibit high efficacy in hybridization with target mRNAs or DNAs (Stein, C.A., et al., In: J.S. Cohen (ed.), *Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression*, pp. 97-117. Boca Raton, FL, CRC Press, Inc. (1989)).

These results demonstrate here for the first time the striking *in vivo* effect of antisense oligodeoxynucleotide in the suppression of malignancy. The depletion of RI<sub>α</sub>, the type I regulatory subunit of cAMP-dependent protein kinase, by means of an antisense oligodeoxynucleotide, especially with its phosphorothioate analog, leads to a successful halt of tumor growth *in vivo* with no symptoms of toxicity, suggesting great potential of this antisense oligodeoxynucleotide for clinical application.

Table 4

Suppression of  $RI_{\alpha}$  cAMP Receptor Expression by  $RI_{\alpha}$  Antisense Oligodeoxynucleotide (S-oligo) Results in Compensatory Increase in  $RII_{\alpha}$  Receptor

| Treatment                       | Relative Levels |                |
|---------------------------------|-----------------|----------------|
|                                 | $RI_{\alpha}$   | $RII_{\beta}$  |
| None                            | $1.0 \pm 0.1$   | $1.0 \pm 0.1$  |
| $RI_{\alpha}$ antisense S-oligo | $0.2 \pm 0.03$  | $2.0 \pm 0.2$  |
| $RII_{\beta}$ antisense S-oligo | $1.5 \pm 0.2$   | $0.2 \pm 0.02$ |
| Random S-oligo                  | $1.0 \pm 0.1$   | $1.0 \pm 0.1$  |

Treatment with S-oligos as indicated were the same as that in Fig. 7B. At the end of the experiment (3 weeks), tumor extracts were prepared as previously described (Ally, S. *et al.*, Cancer Res. 49:5650-5655 (1980)) and immunoblotting and immunoprecipitation of  $RI_{\alpha}$  and  $RII_{\beta}$ , respectively, were performed as previously described by Ally, S., *et al.*, Proc. Natl. Acad. Sci. USA 85:6319-6322 (1988) and Tortora, G., *et al.*, Proc. Natl. Acad. Sci. USA 87:705-708 (1990). Data are from quantification by densitometric scanning of autoradiograms. Data are expressed relative to levels in control tumors (no treatment), which are set to equal to one as an arbitrary unit.

Data represent an average  $\pm$  S.D. of 7 tumors.

In the following sequence listing, Seq ID No: 1 represents an antisense sequence corresponding to the first 7 N-terminal codons for  $RI_{\alpha}$ . Seq ID No: 2 represents an antisense sequence corresponding to the 8<sup>th</sup>-13<sup>th</sup> codon for  $RI_{\alpha}$ . Seq ID No: 3 represents an antisense sequence corresponding to the 14<sup>th</sup>-20<sup>th</sup> codon for  $RI_{\alpha}$ . Seq ID No: 4 represents an antisense sequence corresponding to the 94<sup>th</sup>-100<sup>th</sup> codon for  $RI_{\alpha}$ . Seq ID No: 5 represents an antisense sequence corresponding to the 1<sup>st</sup>-100<sup>th</sup> codon for  $RI_{\alpha}$ . Seq ID No: 6 represents the sense sequence corresponding to the 1<sup>st</sup>-100<sup>th</sup> codon for  $RI_{\alpha}$ .

## SEQUENCE LISTING

## INFORMATION FOR SEQUENCE ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 21 bases  
    (B) TYPE: Nucleic acid  
    (C) STRANDEDNESS: Single  
    (D) TOPOLOGY: Linear

(ii) MOLECULE TYPE: DNA

(iv) ANTISENSE: yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGCGGTACTG CCAGACTCCA T 21

## INFORMATION FOR SEQUENCE ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 18 bases  
    (B) TYPE: Nucleic acid  
    (C) STRANDEDNESS: Single  
    (D) TOPOLOGY: linear

(ii) Molecular TYPE: DNA

(iv) ANTISENSE: yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GCGTGCCTCC TCACTGGC 18

## INFORMATION FOR SEQUENCE ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 21 bases  
    (B) TYPE: Nucleic acid  
    (C) STRANDEDNESS: Single  
    (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(iv) ANTISENSE: yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GAGCTCACAT TCTCGAAGGC T 21

## INFORMATION FOR SEQUENCE ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 bases  
 (B) TYPE: Nucleic acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: linear

## (ii) MOLECULAR TYPE: DNA

## (iv) ANTISENSE: yes

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GATAGCACCT CGTCGCCTCC T 21

## INFORMATION FOR SEQUENCE ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 300 bases  
 (B) TYPE: Nucleic acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: linear

## (ii) MOLECULAR TYPE: DNA

## (iv) ANTISENSE: yes

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GATAGCACCT CGTCGCCTCC TACCTTTAAC CACTGGGTTG GGTGGAGGAG GAGAAATCTC 60  
 ATCCTCCCTT GAGTCTGTAC GAGTGCCTGC TTTCTGCAGA TTGTGAATCT GTTTTGCCTC 120  
 CTCCTTCTCC AACCTCTCAA AGTATTCCCT GAGGAATGCC ATGGGACTCT CAGGTCGAGC 180  
 AGTGACAAC TGCACAATAG AATCTTTGAG CAGTGCTTGA ATGTTATGCT TCTGGACGTA 240  
 GAGCTCATAT TCTCGAAGGC TGCGTGCCTC CTCACTGGCG GCGGTACTGC CAGACTCCAT 300

## INFORMATION FOR SEQUENCE ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 300 bases  
 (B) TYPE: Nucleic acid  
 (C) STRANDEDNESS: Single  
 (D) TOPOLOGY: linear

## (ii) MOLECULAR TYPE: DNA

## (iv) ANTISENSE: yes

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

ATGGAGTCTG GCAGTACCGC CGCCAGTGAG GAGGCACGCA GCCTTCGAGA ATGTGAGCTC 60  
 TACGTCCAGA AGCATAACAT TCAAGCACTG CTCAAAGATT CTATTGTGCA GTTGTGCACT 120  
 GCTCGACCTG AGAGACCCAT GGCATTCTCT AGGGAATACT TTGAGAGGTT GGAGAAGGAG 180  
 GAGGCAAAAC AGATTGAGAA TCTGCAGAAA GCAGGCACTC GTACAGACTC AAGGGAGGAT 240  
 GAGATTTCTC CTCCTCCACC CAACCCAGTG GTTAAAGGTA GGAGGCGACG AGGTGCTATC 300

INFORMATION FOR SEQUENCE ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 bases
- (B) TYPE: Nucleic acid
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: DNA

(iv) ANTISENSE: yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CGATCGATCG ATCGATCGTA C 21

Claims

1. A 15- to 30-mer antisense oligonucleotide which is complementary to a region in the first 100 N-terminal codons of RI<sub>1</sub> (Seq. ID No:6).
2. The antisense oligonucleotide of claim 1 which is DNA.
3. The antisense oligonucleotide of claim 1 which is a 21-mer (Seq. ID No:1).
4. The antisense oligonucleotide of claim 1 which is a 18-mer (Seq. ID No:2).
5. The antisense oligonucleotide of claim 1 which is a 21-mer (Seq. ID No:3).
6. The antisense oligonucleotide of claim 1 which is a 21-mer (Seq. ID No:4).
7. A 15- to 30-mer antisense oligonucleotide which is a fragment of antisense DNA complementary to RI<sub>1</sub> (Seq. ID No: 5).
8. The antisense oligonucleotide of any one of claims 1-7 which is an O-oligonucleotide.
9. The antisense oligonucleotide of any one of claims 1-7 which is an S-oligonucleotide.
10. A pharmaceutical composition comprising at least one 15- to 30-mer antisense oligonucleotide which is complementary to a region in the first 100 N-terminal codons of RI<sub>1</sub> (Seq. ID No:6); and a pharmaceutically acceptable carrier.
11. The pharmaceutical composition of claim 10, comprising two 15- to 30-mer antisense oligonucleotides which are complementary to adjacent regions in the first 100 N-terminal codons of RI<sub>1</sub> (Seq. ID No:6).
12. The pharmaceutical composition of claim 10, wherein said pharmaceutically acceptable carrier is a sterol.
13. The pharmaceutical composition of claim 10, wherein said pharmaceutically acceptable carrier is a liposome.
14. The pharmaceutical composition of claim 10, wherein said antisense oligonucleotide is DNA.
15. The pharmaceutical composition of claim 10, wherein said antisense oligonucleotide is a 21-mer (Seq ID No:1).
16. The pharmaceutical composition of claim 10, wherein said antisense oligonucleotide is an 18-mer (Seq ID No 2).



17. The pharmaceutical composition of claim 10, wherein said antisense oligonucleotide is a 21-mer (Seq. ID No:3).
18. The pharmaceutical composition of claim 10, wherein said antisense oligonucleotide is a 21-mer (Seq. ID No:4).
19. The pharmaceutical composition of claim 10, wherein said 15- to 30-mer antisense oligonucleotide is a fragment of antisense DNA complementary to RI<sub>1</sub> (Seq. ID No: 5).
20. The pharmaceutical composition of claim 10, wherein said antisense oligonucleotide is an O-oligonucleotide.
21. The pharmaceutical composition of claim 10, wherein said antisense oligonucleotide is an S-oligonucleotide.
22. The use of a 15- to 30-mer antisense oligonucleotide which is complementary to a region in the first 100 N-terminal codons of RI<sub>1α</sub> (Seq. ID No:6) for the preparation of a pharmaceutical suitable for treating cancer by suppressing growth of cancer cells susceptible to growth suppression in an animal including human.
23. The use of claim 22, wherein said antisense oligonucleotide is DNA.
24. The use of claim 22, wherein said antisense oligonucleotide is a 21-mer (Seq. ID No:1).
25. The use of claim 22, wherein said antisense oligonucleotide is an 18-mer (Seq. ID No:2).
26. The use of claim 22, wherein said antisense oligonucleotide is a 21-mer (Seq. ID No:3).
27. The use of claim 22, wherein said antisense oligonucleotide is a 21-mer (Seq. ID No:4).
28. The use of claim 22, wherein said 15- to 30-mer antisense oligonucleotide is a fragment of antisense DNA complementary to the RI<sub>1</sub> codons (Seq. ID No: 5).
29. The use of claim 22, wherein said cancer is selected from the group consisting of leukemia, melanoma, sarcoma, and carcinoma.
30. The use of claim 22, wherein said antisense oligonucleotide is administered as part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
31. The use of claim 22, wherein said antisense oligonucleotide is an O-oligonucleotide.
32. The use of claim 22, wherein said antisense oligonucleotide is an S-oligonucleotide.

FIG.1





FIG.2




FIG.3





FIG. 4



| Lane | Treatment                     | Relative Levels |               |
|------|-------------------------------|-----------------|---------------|
|      |                               | $RI_{\alpha}$   | $RI_{\beta}$  |
| 1    | Control                       | $1.0 \pm 0.1$   | $1.0 \pm 0.1$ |
| 2    | 8-Cl + N <sup>6</sup> -Benzyl | $0.3 \pm 0.04$  | $3.0 \pm 0.3$ |
| 3    | $RI_{\alpha}$ Antisense       | $0.2 \pm 0.03$  | $5.0 \pm 0.4$ |

FIG. 5




FIG. 6





FIG. 7







European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number

EP 91 11 8628

Page 1

| DOCUMENTS CONSIDERED TO BE RELEVANT   |   |  |  |
|---|---|--|--|
| Category  | Citation of document with indication, where appropriate, of relevant passages   | Relevant to claim  | CLASSIFICATION OF THE APPLICATION (Int. Cl.5)                        |
| X   | PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH<br>vol. 31, March 1990,<br>page 29;<br>CHO-CHUNG, Y.S. ET AL.: 'A RI-alpha subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase blocks proliferation in human and rodent cancer cell lines by passing exogenous cAMP effect'<br>* Right column; Abstract 171 *   | 1-3,5-8,<br>22-24,<br>26-31  | C12N15/11<br>A61K31/70<br>C07H21/00                                  |
| X   | PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH<br>vol. 31, March 1990,<br>page 38;<br>TORTORA, G. ET AL.: 'A RI-alpha antisense oligodeoxynucleotide of c-AMP-dependent protein kinase inhibits proliferation of human HL-60 promyelocytic leukemia'<br>* Left column; Abstract 220 *  | 1-3,5-8,<br>22-24,<br>26-31  |  |
| X   | PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,<br>vol. 87, January 1990, WASHINGTON US<br>pages 705 - 708;<br>TORTORA, G. ET AL.: 'An antisense oligodeoxynucleotide targeted against the type II-beta regulatory subunit mRNA of protein kinase inhibits cAMP induced differentiation in HL-60 leukemia cells without affecting phorbol ester effects'<br>* page 705, right column, paragraph 4 * | 1-3,7-8,<br>10,<br>14-15,<br>19-20,<br>22-24,<br>28-31   | TECHNICAL FIELDS<br>SEARCHED (Int. Cl.5)<br><br>C12N<br>C07H<br>A61K |
| Y   | * page 707, right column, paragraph 2 *   | 9-13,21,<br>30,32  |  |
| ---   |   |  |  |
| -/--  |   |  |  |
| The present search report has been drawn up for all claims  |   |  |  |
| Place of search<br>THE HAGUE  |   | Date of completion of the search<br>30 JANUARY 1992  | Examiner<br>ANDRES S.M.  |
| CATEGORY OF CITED DOCUMENTS   |   |  |  |
| X : particularly relevant if taken alone<br>Y : particularly relevant if combined with another document of the same category<br>A : technological background<br>O : non-written disclosure<br>P : intermediate document |   | T : theory or principle underlying the invention<br>E : earlier patent document, but published on, or after the filing date<br>D : document cited in the application<br>L : document cited for other reasons<br>A : member of the same patent family, corresponding document |  |



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number

EP 91 11 8628

Page 2

| DOCUMENTS CONSIDERED TO BE RELEVANT  |   |  |   |
|--|---|--|---|
| Category   | Citation of document with indication, where appropriate, of relevant passages   | Relevant to claim                                      | CLASSIFICATION OF THE APPLICATION (Int. Cl.5) |
| D,Y  | JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,<br>vol. 112, no. 3, 31 January 1990, GASTON, PA US<br>pages 1253 - 1254;<br>IYER, R.P. ET AL.: '3H-1,2-benzodithiole-3-one<br>1,1-dioxide as an improved sulfurizing reagent<br>in the solid-phase synthesis of<br>oligodeoxyribonucleoside phosphorothioates'<br>* the whole document *  | 9,21,32  |   |
| Y  | WO-A-9 009 180 (BOARD OF REGENTS, THE UNIVERSITY<br>OF TEXAS SYSTEM)<br>* page 36, line 13 - line 23 *  | 10-13,30   |   |
| A  | * page 14 - page 15; claims *   | 1-32   |   |
| P,X  | PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES<br>OF USA,<br>vol. 88, March 1991, WASHINGTON US<br>pages 2011 - 2015;<br>TORTORA, G. ET AL.: 'Differentiation of HL-60<br>leukemia by type I regulatory subunit antisense<br>oligodeoxynucleotide of cAMP-dependent protein<br>kinase'<br>* the whole document *   | 1-3,7-8,<br>10,<br>14-15,<br>19-20,<br>22-24,<br>28-31 | TECHNICAL FIELDS<br>SEARCHED (Int. Cl.5)      |
| P,X  | PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR<br>CANCER RESEARCH<br>vol. 32, March 1991,<br>page 277;<br>CLAIR, T. ET AL.: 'An antisense<br>oligodeoxynucleotide targeted against the type I<br>regulatory subunit (RI-alpha) mRNA of<br>cAMP-dependent protein kinase (PKA) inhibits the<br>growth of LS-174T human colon carcinoma in<br>athymic mice'<br>* Right column; Abstract 1645 * | 1-3,5-7,<br>9,22-24,<br>26-30,32                       |   |
| The present search report has been drawn up for all claims   |   |  |   |
| Place of search<br>THE HAGUE   |   | Date of completion of the search<br>30 JANUARY 1992    | Examiner<br>ANDRES S.M.                       |
| <b>CATEGORY OF CITED DOCUMENTS</b><br>X : particularly relevant if taken alone<br>Y : particularly relevant if combined with another<br>document of the same category<br>A : technological background<br>O : non-written disclosure<br>P : intermediate document<br>T : theory or principle underlying the invention<br>E : earlier patent document, but published on, or<br>after the filing date<br>D : document cited in the application<br>L : document cited for other reasons<br>& : member of the same patent family, corresponding<br>document |   |  |   |